March 14, 2013 – FDA announces investigation into pancreatic cancer risk with Onglyza and other incretin mimetic diabetes drugs.
March 14, 2013 – FDA announces investigation into pancreatic cancer risk with Onglyza and other incretin mimetic diabetes drugs.